-
This was somewhat of a first for the US FDA to trust Chinese data. Shenzhen Chipscreen Bio sciences Ltd. was also awarded the Most Valued Partner for Roche R&D Center. Oncology drugs are one of their primary focuses, with individuals trained here in the US and returning to China to create their...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-15-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, FDA, Oncology, R and D, China pharma, Chipscreen, biosciences, HUYA
-
The bar has also risen on Venture Capital money and is harder to get, and so much of the research is still in the “Science” stage, there have been a few companies that have had failed products and just folded up and went away. This certainly leaves the door open for Pharma, who has the financials...
-
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
-
Recently announced is the project to begin at Scripps in San Diego as related news, coupled with the announcement of the new sequencing service that will be able to offer a complete sequence at a wholesale price may have held a bit of inspiration here for Navigenics to enter the full sequencing market...
-
This is not welcome news by any means for the VC money that was invested. A redirection of the product was too costly as well, thus they shop closes with million invested and a loss. The FDA restrictions also played a role in the limiting of consumer clinical trials here, so with a series...
-
Not only do we see venture capital money here, also some big Pharma names. In a related story, Roche sees diagnostic machines and test kits as crucial to assessing and treating disease in the future and their risk profile has recognition of being one large investor in a growing area of drug research...
-
In other words, this is called Business Intelligence. Lots of it out there to choose from and one from Microsoft specifically related to hospital management and budgets. Before the demise of Wall Street it wasn’t too long ago that I posted about the All Nighter they pulled to mine and try...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-26-2008
Filed under:
Filed under: Medically Related, Technology, Other Items of Interest, My Commentaries, Pharma, Biotech, Cancer, Business Intelligence, R and D, Wall Street, Pricing
-
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
-
All over healthcare the big fish, little fish story is either taking place or actions are in the making for offers. There certainly are a number of big Pharma companies with money to foot the bill, that is if the Biotech companies see it fit to consider the options. One problem as indicated in...
-
More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on claims, etc. No...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-18-2008
Filed under:
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, health insurance, healthcare IT, Pharma, Biotech, FDA, Medco, Pharmacogonomics
-
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...
-
Discussed here is the recent law in Massachusetts relative to gifts, etc. just recently passed. Being the CEO of BIO, the biotech industry trade group, of course there's an interest in not having funds diminished, but also addresses the interest of the public. With all the recent Pharma...
-
Update: Are 3 minds better than one? It certainly appears this could be the case, at least when it comes to clinical trials and getting the right type of participants to enroll and some forecasting to make sure the drugs will succeed. What is the target here, the big crystal...
-
Interview with a company that has settled in Bejiing, China explains why...cost is one issue coming in at one third the amount required here in the United States...and another is the availability of scientists...we all think cost is the only area that drives business overseas, but this is another added...